News | June 30, 2023
Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Subscribe To Our Newsletter & Stay Updated
